9.25

0.33% +0.03

Neumora Therapeutics Inc. (NMRA)

Overview News Price History Option Chain Financials Why NMRA Down? Discussions Forecast

Neumora Therapeutics Inc. stock is currently priced at $9.25, with a 24-hour trading volume of 377.70K. It has seen a +0.33% increased in the last 24 hours and a -30.45% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $9.11 pivot point. If it approaches the $9.38 resistance level, significant changes may occur.

Previous Close:

$9.22

Open:

$9.22

24h Volume:

377.70K

Market Cap:

$1.47B

Revenue:

Net Income/Loss:

$-219.25M

P/E Ratio:

-5.3835

EPS:

-1.7182

Net Cash Flow:

$-115.41M

1W Performance:

+1.09%

1M Performance:

-30.45%

6M Performance:

-21.94%

1Y Performance:

+0.00%

1D Range:

$9.21

$9.66

52W Range:

$8.82

$21.00

Neumora Therapeutics Inc. Stock (NMRA) Company Profile

Name

Neumora Therapeutics Inc.

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

857-760-0900

Address

490 Arsenal Way, Suite 200, Watertown

Employee

110

Twitter

Next Earnings Date

Latest SEC Filings

NMRA's Discussions on Twitter

Neumora Therapeutics Inc. Stock (NMRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-12-23	Initiated	Deutsche Bank	Hold
Oct-10-23	Initiated	BofA Securities	Buy
Oct-10-23	Initiated	Guggenheim	Buy
Oct-10-23	Initiated	JP Morgan	Overweight
Oct-10-23	Initiated	RBC Capital Mkts	Outperform
Oct-10-23	Initiated	Stifel	Buy
Oct-10-23	Initiated	William Blair	Outperform

View All

Neumora Therapeutics Inc. Stock (NMRA) Latest News

Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success

Zacks Investment Research

Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug

Zacks Investment Research

S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March

Benzinga

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

Crude Oil Down 1%; Charles Schwab Sales Top Estimates

Benzinga

Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Benzinga

Neumora Therapeutics Inc. Stock (NMRA) Financials Data

Neumora Therapeutics Inc. (NMRA) Net Income 2024

NMRA net income (TTM) was -$219.25 million for the quarter ending December 31, 2023, a +21.25% increase year-over-year.

Neumora Therapeutics Inc. (NMRA) Cash Flow 2024

NMRA recorded a free cash flow (TTM) of -$115.41 million for the quarter ending December 31, 2022, a -51.38% decrease year-over-year.

Neumora Therapeutics Inc. (NMRA) Earnings per Share 2024

NMRA earnings per share (TTM) was -$2.2029 for the quarter ending December 31, 2023, a -20.23% decline year-over-year.

Neumora Therapeutics Inc. Stock (NMRA) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
ARCH Venture Partners XII, LLC	10% Owner	Nov 14 '23	Buy	11.98	3,357	40,217	4,131,207
ARCH Venture Partners XII, LLC	10% Owner	Nov 13 '23	Buy	11.75	31,653	371,923	4,127,850
Burow Kristina	Director	Nov 13 '23	Buy	11.75	31,653	371,923	4,127,850
Burow Kristina	Director	Nov 10 '23	Buy	11.49	17,275	198,481	4,096,197
ARCH Venture Partners XII, LLC	10% Owner	Nov 10 '23	Buy	11.49	17,275	198,481	4,096,197
ARCH Venture Partners XII, LLC	10% Owner	Nov 09 '23	Buy	10.53	31,079	327,262	4,078,922
Burow Kristina	Director	Nov 09 '23	Buy	10.53	31,079	327,262	4,078,922
Burow Kristina	Director	Nov 08 '23	Buy	11.03	92,251	1,017,821	4,047,843
ARCH Venture Partners XII, LLC	10% Owner	Nov 08 '23	Buy	11.03	92,251	1,017,821	4,047,843
Burow Kristina	Director	Nov 07 '23	Buy	11.50	30,192	347,208	3,955,592

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. The company was incorporated in 2019 and is headquartered in Watertown, Massachusetts.